Glenview Trust co lowered its stake in shares of Waters Co. (NYSE:WAT - Free Report) by 13.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,337 shares of the medical instruments supplier's stock after selling 1,100 shares during the period. Glenview Trust co's holdings in Waters were worth $2,722,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Assetmark Inc. lifted its position in Waters by 16.5% during the third quarter. Assetmark Inc. now owns 1,200 shares of the medical instruments supplier's stock worth $432,000 after buying an additional 170 shares in the last quarter. Atria Investments Inc grew its stake in shares of Waters by 10.3% in the 3rd quarter. Atria Investments Inc now owns 3,141 shares of the medical instruments supplier's stock valued at $1,130,000 after buying an additional 294 shares during the period. Huntington National Bank lifted its holdings in Waters by 3.6% in the third quarter. Huntington National Bank now owns 1,377 shares of the medical instruments supplier's stock valued at $496,000 after acquiring an additional 48 shares during the last quarter. OneDigital Investment Advisors LLC grew its position in Waters by 3.8% in the third quarter. OneDigital Investment Advisors LLC now owns 851 shares of the medical instruments supplier's stock worth $306,000 after acquiring an additional 31 shares during the period. Finally, CIBC Asset Management Inc increased its stake in Waters by 8.2% during the third quarter. CIBC Asset Management Inc now owns 8,780 shares of the medical instruments supplier's stock worth $3,160,000 after acquiring an additional 662 shares during the last quarter. 94.01% of the stock is owned by hedge funds and other institutional investors.
Waters Stock Performance
Waters stock traded up $1.49 during mid-day trading on Tuesday, reaching $380.41. 301,014 shares of the company were exchanged, compared to its average volume of 436,843. The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.65 and a current ratio of 0.94. The firm's 50-day simple moving average is $391.26 and its two-hundred day simple moving average is $370.72. Waters Co. has a twelve month low of $279.24 and a twelve month high of $423.56. The firm has a market cap of $22.60 billion, a PE ratio of 35.46, a price-to-earnings-growth ratio of 3.79 and a beta of 1.00.
Waters (NYSE:WAT - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.02 by $0.08. Waters had a return on equity of 46.31% and a net margin of 21.56%. Equities analysts predict that Waters Co. will post 12.86 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on WAT shares. Scotiabank upgraded Waters from a "sector perform" rating to a "sector outperform" rating and increased their price target for the stock from $430.00 to $450.00 in a report on Thursday, February 13th. Sanford C. Bernstein raised shares of Waters from a "market perform" rating to an "outperform" rating and set a $430.00 price target on the stock in a research note on Friday, January 10th. Wells Fargo & Company increased their price objective on shares of Waters from $415.00 to $420.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Bank of America decreased their price target on Waters from $430.00 to $410.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. lifted their price objective on Waters from $380.00 to $390.00 and gave the company a "neutral" rating in a research note on Thursday, March 6th. Eleven analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $391.07.
Read Our Latest Stock Analysis on Waters
Waters Profile
(
Free Report)
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Featured Articles
Before you consider Waters, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waters wasn't on the list.
While Waters currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
